DR. PETER NAVARRO – UNDERSTANDING WHY THE VAX IS FAILING – 1/30/2022

DR PETER NAVARRO – ON GETTER
DR. PETER NAVARRO, ASSISTANT TO THE PRESIDENT FOR TRADE and MANUFACTURING POLICY, PANDEMIC DEFENSE PRODUCTION ACT POLICY COORDINATOR - CREATOR OF “IN TRUMP TIME” - A JOURNAL OF AMERICA’S PLAGUE YEAR

CLICK THE LINK BELOW FOR THE ENTIRE POST FROM THE NATIONAL LIBRARY OF MEDICINE –

https://www.ncbi.nlm.nih.gov/

What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2?

Marc Hellerstein 1 2Affiliations expand

Free PMC article

Abstract

The first SARS-CoV-2 vaccine(s) will likely be licensed based on neutralizing antibodies in Phase 2 trials, but there are significant concerns about using antibody response in coronavirus infections as a sole metric of protective immunity. Antibody response is often a poor marker of prior coronavirus infection, particularly in mild infections, and is shorter-lived than virus-reactive T-cells; strong antibody response correlates with more severe clinical disease while T-cell response is correlated with less severe disease; and antibody-dependent enhancement of pathology and clinical severity has been described. Indeed, it is unclear whether antibody production is protective or pathogenic in coronavirus infections. Early data with SARS-CoV-2 support these findings. Data from coronavirus infections in animals and humans emphasize the generation of a high-quality T cell response in protective immunity. Yellow Fever and smallpox vaccines are excellent benchmarks for primary immune response to viral vaccination and induce long-lived virus-reactive CD8 T-cells, which are present and measurable within 1-4 months of vaccination. Progress in laboratory markers for SARS-CoV2 has been made with identification of epitopes on CD4 and CD8 T-cells in convalescent blood. These are much less dominated by spike protein than in previous coronavirus infections. Although most vaccine candidates are focusing on spike protein as antigen, natural infection by SARS-CoV-2 induces broad epitope coverage, cross-reactive with other betacoronviruses. It will be important to understand the relation between breadth, functionality and durability of T-cell responses and resulting protective immunity. It would be a public health and general trust-in-medicine nightmare – including a boost to anti-vaccine forces – if immune protection wears off or new disease patterns develop among the immunized. Data correlating clinical outcomes with laboratory markers of cell-mediated immunity, not only with antibody response, after SARS-CoV-2 natural infection and vaccines may prove critically valuable if protective immunity fades or if new patterns of disease emerge.

Keywords: Antibodies; Antibody-dependent enhancement; CD8 T-cells; COVID-19; Durable immunity; Protective immunity; SARS; SARS-CoV-2; T cell lifespan; T-cell epitopes; T-cells; Vaccines; Yellow Fever Vaccine.

10

%d bloggers like this:
Skip to toolbar